News Release


Execution of License Agreement on Neramexane for Tinnitus with Merz Pharmaceuticals for Japan Territory

November 5, 2009

KYORIN Pharmaceutical Co., Ltd. ("Kyorin") (Head office: Chiyoda-ku, Tokyo, President: Keiji Hirai, Ph.D.), a wholly owned subsidiary of KYORIN Co., Ltd., today entered into a License Agreement for Neramexane, a tinnitus treatment product currently being developed in the US and Europe, with Merz Pharmaceuticals GmbH ("Merz") (Head office: Frankfurt am Main, Germany, CEO: Martin Zügel, Ph.D.) for the territory of Japan.

Get Adobe Acrobat Reader

Adobe Reader software is required to view and print PDF files. The latest version of Adobe Reader can be downloaded by accessing the Adobe Systems Incorporated website.